These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
743 related articles for article (PubMed ID: 18220746)
21. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Ying W; Du Z; Sun L; Foley KP; Proia DA; Blackman RK; Zhou D; Inoue T; Tatsuta N; Sang J; Ye S; Acquaviva J; Ogawa LS; Wada Y; Barsoum J; Koya K Mol Cancer Ther; 2012 Feb; 11(2):475-84. PubMed ID: 22144665 [TBL] [Abstract][Full Text] [Related]
22. Alleviating neurodegeneration by an anticancer agent: an Hsp90 inhibitor (17-AAG). Waza M; Adachi H; Katsuno M; Minamiyama M; Tanaka F; Sobue G Ann N Y Acad Sci; 2006 Nov; 1086():21-34. PubMed ID: 17185503 [TBL] [Abstract][Full Text] [Related]
23. 17-DMAG induces heat shock protein 90 functional impairment in human bladder cancer cells: knocking down the hallmark traits of malignancy. Karkoulis PK; Stravopodis DJ; Voutsinas GE Tumour Biol; 2016 May; 37(5):6861-73. PubMed ID: 26662567 [TBL] [Abstract][Full Text] [Related]
24. Design of novel Geldanamycin analogue hsp90 alpha-inhibitor in silico for breast cancer therapy. Mahanta S; Pilla S; Paul S Med Hypotheses; 2013 Sep; 81(3):463-9. PubMed ID: 23860250 [TBL] [Abstract][Full Text] [Related]
25. Retaspimycin hydrochloride (IPI-504): a novel heat shock protein inhibitor as an anticancer agent. Hanson BE; Vesole DH Expert Opin Investig Drugs; 2009 Sep; 18(9):1375-83. PubMed ID: 19642950 [TBL] [Abstract][Full Text] [Related]
27. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90. Ge J; Normant E; Porter JR; Ali JA; Dembski MS; Gao Y; Georges AT; Grenier L; Pak RH; Patterson J; Sydor JR; Tibbitts TT; Tong JK; Adams J; Palombella VJ J Med Chem; 2006 Jul; 49(15):4606-15. PubMed ID: 16854066 [TBL] [Abstract][Full Text] [Related]
28. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo. Schwock J; Pham NA; Cao MP; Hedley DW Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866 [TBL] [Abstract][Full Text] [Related]
30. Mechanistic studies on Hsp90 inhibition by ansamycin derivatives. Onuoha SC; Mukund SR; Coulstock ET; Sengerovà B; Shaw J; McLaughlin SH; Jackson SE J Mol Biol; 2007 Sep; 372(2):287-97. PubMed ID: 17662999 [TBL] [Abstract][Full Text] [Related]
31. Potent cytotoxic C-11 modified geldanamycin analogues. Tian ZQ; Wang Z; MacMillan KS; Zhou Y; Carreras CW; Mueller T; Myles DC; Liu Y J Med Chem; 2009 May; 52(10):3265-73. PubMed ID: 19405528 [TBL] [Abstract][Full Text] [Related]
32. Targeting heat-shock-protein 90 (Hsp90) by natural products: geldanamycin, a show case in cancer therapy. Franke J; Eichner S; Zeilinger C; Kirschning A Nat Prod Rep; 2013 Oct; 30(10):1299-323. PubMed ID: 23934201 [TBL] [Abstract][Full Text] [Related]
33. Silencing of HSP90 cochaperone AHA1 expression decreases client protein activation and increases cellular sensitivity to the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Holmes JL; Sharp SY; Hobbs S; Workman P Cancer Res; 2008 Feb; 68(4):1188-97. PubMed ID: 18281495 [TBL] [Abstract][Full Text] [Related]
34. Histone deacetylase activity mediates acquired resistance towards structurally diverse HSP90 inhibitors. Chai RC; Vieusseux JL; Lang BJ; Nguyen CH; Kouspou MM; Britt KL; Price JT Mol Oncol; 2017 May; 11(5):567-583. PubMed ID: 28306192 [TBL] [Abstract][Full Text] [Related]
35. Design, synthesis and biological evaluation of 17-arylmethylamine-17-demethoxygeldanamycin derivatives as potent Hsp90 inhibitors. Li Z; Jia L; Wang J; Wu X; Hao H; Xu H; Wu Y; Shi G; Lu C; Shen Y Eur J Med Chem; 2014 Oct; 85():359-70. PubMed ID: 25105924 [TBL] [Abstract][Full Text] [Related]
36. Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling. Al Shaer L; Walsby E; Gilkes A; Tonks A; Walsh V; Mills K; Burnett A; Rowntree C Br J Haematol; 2008 May; 141(4):483-93. PubMed ID: 18373709 [TBL] [Abstract][Full Text] [Related]
37. Discovery of novel 17-phenylethylaminegeldanamycin derivatives as potent Hsp90 inhibitors. Li Z; Jia L; Wang J; Wu X; Shi G; Lu C; Shen Y Chem Biol Drug Des; 2015 Feb; 85(2):181-8. PubMed ID: 24903735 [TBL] [Abstract][Full Text] [Related]
38. Cucurbitacin D Is a Disruptor of the HSP90 Chaperone Machinery. Hall JA; Seedarala S; Rice N; Kopel L; Halaweish F; Blagg BS J Nat Prod; 2015 Apr; 78(4):873-9. PubMed ID: 25756299 [TBL] [Abstract][Full Text] [Related]
39. Suppression of heat shock protein 27 using OGX-427 induces endoplasmic reticulum stress and potentiates heat shock protein 90 inhibitors to delay castrate-resistant prostate cancer. Lamoureux F; Thomas C; Yin MJ; Fazli L; Zoubeidi A; Gleave ME Eur Urol; 2014 Jul; 66(1):145-55. PubMed ID: 24411988 [TBL] [Abstract][Full Text] [Related]
40. Discovery of diamine-linked 17-aroylamido-17-demethoxygeldanamycins as potent Hsp90 inhibitors. Li Z; Jia L; Wang J; Wu X; Hao H; Wu Y; Xu H; Wang Z; Shi G; Lu C; Shen Y Eur J Med Chem; 2014 Nov; 87():346-63. PubMed ID: 25277067 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]